Robyn Karnauskas
Stock Analyst at Truist Securities
(1.70)
# 3,224
Out of 4,886 analysts
183
Total ratings
42.31%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $4.03 | +148.14% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $292.95 | +1.72% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $46.49 | +39.82% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $80.90 | +35.97% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $111.78 | -25.75% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $187.63 | +11.92% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.69 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $130.13 | +161.28% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $1.74 | +1,394.25% | 2 | May 15, 2024 | |
| CHRS Coherus Oncology | Maintains: Buy | $8 → $7 | $0.75 | +838.09% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $538.11 | +110.92% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.87 | +434.76% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $2.58 | +248.84% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $74 | $15.96 | +363.66% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $10.74 | +114.15% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $16.42 | +192.33% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $8.22 | +508.27% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $850 | $772.87 | +9.98% | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $459.41 | +10.58% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $25.24 | +42.63% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $47.98 | -47.89% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.90 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $57.41 | +143.86% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $0.05 | +300,501.20% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.06 | +560.38% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $14.31 | +284.35% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.62 | - | 4 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $23.64 | +1,253.64% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $3.71 | +304.31% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.41 | +633.14% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.34 | +25,227.77% | 1 | Oct 8, 2020 |
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $4.03
Upside: +148.14%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $292.95
Upside: +1.72%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $46.49
Upside: +39.82%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $80.90
Upside: +35.97%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $111.78
Upside: -25.75%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $187.63
Upside: +11.92%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.69
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $130.13
Upside: +161.28%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $1.74
Upside: +1,394.25%
Coherus Oncology
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $0.75
Upside: +838.09%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $538.11
Upside: +110.92%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.87
Upside: +434.76%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $2.58
Upside: +248.84%
Mar 25, 2024
Reiterates: Buy
Price Target: $74
Current: $15.96
Upside: +363.66%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $10.74
Upside: +114.15%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $16.42
Upside: +192.33%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $8.22
Upside: +508.27%
Mar 22, 2024
Reiterates: Buy
Price Target: $850
Current: $772.87
Upside: +9.98%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $459.41
Upside: +10.58%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $25.24
Upside: +42.63%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $47.98
Upside: -47.89%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.90
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $57.41
Upside: +143.86%
Sep 6, 2023
Reiterates: Buy
Price Target: $150
Current: $0.05
Upside: +300,501.20%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.06
Upside: +560.38%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $14.31
Upside: +284.35%
Dec 6, 2022
Downgrades: Hold
Price Target: n/a
Current: $2.62
Upside: -
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $23.64
Upside: +1,253.64%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $3.71
Upside: +304.31%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $3.41
Upside: +633.14%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.34
Upside: +25,227.77%